normothermic-negative-pressure-ventilation-ex-situ-lung-perfusion

Normothermic Negative Pressure Ventilation <em>Ex Situ</em> Lung Perfusion: Evaluation of Lung Function and Metabolism

Lung transplantation (LTx) remains the standard of care for end-stage lung disease. A shortage of suitable donor organs and concerns over donor organ ...

left-lung-orthotopic-transplantation-juvenile-porcine-model-for

Left Lung Orthotopic Transplantation in a Juvenile Porcine Model for ESLP

Lung transplantation is the gold-standard treatment for end-stage lung disease, with over 4,600 lung transplantations performed worldwide annually. ...

University of Alberta

This prospective study assessed lymphocyte subsets in the peripheral blood of 42 islet allograft recipients using flow cytometry from 2 weeks and up to 2 years post-transplantation. Subjects received daclizumab (n = 16), Thymoglobulin (n = 12) or alemtuzumab (n = 14). Alemtuzumab was associated with an early (within 1 month) and transient (up to 6 months) increase in the frequency of CD3(+) CD4(+) Foxp3(+) T cells, while daclizumab induced a near complete loss of these cells (P <or= 0.001). The frequency of memory CD4(+) T cells was increased following depleting immunosuppression induction with either Thymoglobulin or alemtuzumab (P <or= 0.05), but remained unchanged while using daclizumab. Alemtuzumab induction resulted in a significant loss of memory B lymphocytes when compared with the other induction groups (P <or= 0.001). While the clinical significance of these findings remains to be fully determined, the observed altered balance between effector, regulatory and memory cells suggests that the immune status of patients will be affected according to the induction strategy chosen.

Effect of different induction strategies on effector, regulatory and memory lymphocyte sub-populations in clinical islet transplantation.

Cette &eacute;tude prospective a &eacute;valu&eacute; des sous-ensembles de lymphocytes dans le sang p&eacute;riph&eacute;rique de 42 receveurs d&#39;une allogreffe &icirc;lot cytom&eacute;trie de 2 semaines et jusqu&#39;&agrave; apr&egrave;s 2 ans. Sujets ont re&ccedil;u daclizumab (n = 16), Thymoglobulin (n = 12) ou l&#39;alemtuzumab (n = 14). Alemtuzumab a &eacute;t&eacute; associ&eacute;e &agrave; un pr&eacute;coce (&agrave; moins de 1 mois) et transitoire (jusqu&#39;&agrave; 6 mois) d&#39;augmenter la fr&eacute;quence des Foxp3(+) CD3(+) CD4 + T des cellules, tandis que daclizumab induit une perte quasie compl&egrave;te de ces cellules (P &lt; ou = 0, 001). La fr&eacute;quence des cellules T CD4 + m&eacute;moire a &eacute;t&eacute; augment&eacute;e suite appauvrissant la couche d&#39;induction d&#39;immunosuppression avec Thymoglobulin ou alemtuzumab (P &lt; ou = 0,05), mais est demeur&eacute;e inchang&eacute;e, tout en utilisant le daclizumab. Induction de l&#39;alemtuzumab a entra&icirc;n&eacute; une perte importante des lymphocytes B m&eacute;moire en comparaison avec les autres groupes d&#39;induction (P &lt; ou = 0, 001). Alors que la signification clinique de ces r&eacute;sultats n&#39;est toujours pas enti&egrave;rement r&eacute;solu, l&#39;&eacute;quilibre alt&eacute;r&eacute; observ&eacute;e entre effecteur, r&eacute;glementation et cellules m&eacute;moires sugg&egrave;re que le statut immunitaire des patients est affect&eacute; selon la strat&eacute;gie d&#39;induction choisie.

Effet des strat&eacute;gies diff&eacute;rentes d&#39;induction sur l&#39;effecteur, r&eacute;glementation et sous-populations de lymphocytes de m&eacute;moire dans la transplantation d&#39;&icirc;lots clinique.

Questo studio prospettico ha valutato i sottoinsiemi dei linfociti nel sangue periferico di 42 destinatari di allotrapianto isolotto mediante citometria a flusso da 2 settimane e fino a post-trapianto 2 anni. Soggetti ricevuti daclizumab (n = 16), Thymoglobulin (n = 12) o alemtuzumab (n = 14). Alemtuzumab &egrave; stato associato con un precoce (entro 1 mese) e transitori (fino a 6 mesi) aumentare la frequenza di CD3(+) CD4(+) Foxp3(+) T cellule, mentre daclizumab indotta vicina perdita completa di queste cellule (P &lt; o = 0,001). La frequenza di cellule T CD4(+) di memoria &egrave; stata aumentata dopo induzione di immunosoppressione lesive con Thymoglobulin o alemtuzumab (P &lt; o = 0,05), ma &egrave; rimasto invariato durante l&#39;utilizzo di daclizumab. Alemtuzumab induzione ha provocato una perdita significativa di linfociti B memoria quando confrontato con gli altri gruppi di induzione (P &lt; o = 0,001). Mentre il significato clinico di questi risultati rimane per essere completamente determinata, l&#39;equilibrio alterato osservato tra effector, regolamentazione e cellule di memoria suggerisce che lo stato immunitario dei pazienti sar&agrave; interessato secondo la strategia di induzione scelta.

Effetto delle strategie di induzione differente su effector, regolamentazione e sottopopolazioni linfocitarie memoria nel trapianto clinico isolotto.

Although insulin independence is maintained in most islet recipients at 1 yr after transplant, extended follow-up has revealed that many patients will eventually require insulin therapy. Previous studies have shown that islet autografts are prone to chronic failure in large animals and humans, suggesting that nonimmunological events contribute to islet graft functional decay. Early intervention with therapies that promote graft stability should provide a measurable benefit over time. In this study, the efficacy of the long-acting glucagon-like peptide-1 analog liraglutide was explored in a porcine marginal mass islet autograft transplant model. Incubation with liraglutide enhanced porcine islet survival and function after prolonged culture. Most vehicle-treated (83%) and liraglutide-treated (80%) animals became insulin independent after islet autotransplantation. Although liraglutide therapy did not improve insulin independence rates or blood glucose levels after transplant, a significant increase in insulin secretion and acute-phase insulin response was observed in treated animals. Surprisingly, no evidence for deterioration of graft function was observed in any of the transplanted animals over more than 18 months of follow-up despite significant weight gain; in fact, an enhanced response to glucose developed over time even in control animals. Histological analysis showed that intraportally transplanted islets remained highly insulin positive, retained alpha-cells, and did not form amyloid deposits. This study demonstrates that marginal mass porcine islet autografts have stable long-term function, even in the presence of an increasing metabolic demand. These results are discrepant with previous large animal studies and suggest that porcine islets may be resistant to metabolic failure.

Porcine marginal mass islet autografts resist metabolic failure over time and are enhanced by early treatment with liraglutide.

Bien que l&#39;ind&eacute;pendance de l&#39;insuline est maintenue dans la plupart des b&eacute;n&eacute;ficiaires &icirc;lot &agrave; 1 an apr&egrave;s la transplantation, prolong&eacute; suivi a r&eacute;v&eacute;l&eacute; que de nombreux patients n&eacute;cessiteront &eacute;ventuellement insulinoth&eacute;rapie. Des &eacute;tudes ant&eacute;rieures ont montr&eacute; qu&#39;&icirc;lot autogreffes sont sujettes &agrave; l&#39;insuffisance chronique de grands animaux et les humains, ce qui sugg&egrave;re que des &eacute;v&eacute;nements nonimmunological contribuent &agrave; l&#39;&icirc;lot de greffe d&eacute;composition fonctionnelle. Une intervention pr&eacute;coce avec les th&eacute;rapies qui favorisent la stabilit&eacute; de la proth&egrave;se doit fournir un avantage mesurable au fil du temps. Dans cette &eacute;tude, l&#39;efficacit&eacute; de l&#39;action prolong&eacute;e le glucagon-like peptide-1 analogique liraglutide a &eacute;t&eacute; &eacute;tudi&eacute;e dans un mod&egrave;le porcin &icirc;lot masse marginal de greffe autogreffe. D&#39;incubation avec le liraglutide am&eacute;lior&eacute; la survie &icirc;lot porcin et la fonction apr&egrave;s culture prolong&eacute;e. Plus impr&eacute;gn&eacute;es sur le v&eacute;hicule (83 %) et les animaux (80 %) trait&eacute;s liraglutide est devenu ind&eacute;pendant de l&#39;insuline apr&egrave;s autotransplantation de l&#39;&icirc;lot. Liraglutide th&eacute;rapie n&#39;a pas am&eacute;lior&eacute; le taux d&#39;ind&eacute;pendance de l&#39;insuline ou le taux de glucose sanguin apr&egrave;s transplantation, une augmentation significative de la s&eacute;cr&eacute;tion d&#39;insuline et de la r&eacute;ponse de phase aigu&euml; l&#39;insuline a &eacute;t&eacute; observ&eacute;e chez les animaux trait&eacute;s. &Eacute;tonnamment, aucun signe de d&eacute;t&eacute;rioration de la fonction du greffon a &eacute;t&eacute; observ&eacute; dans aucun des animaux transplant&eacute;s pendant plus de 18 mois de suivi malgr&eacute; le gain de poids significatif ; en fait, une meilleure r&eacute;ponse au glucose d&eacute;velopp&eacute; au fil du temps, m&ecirc;me chez les animaux t&eacute;moins. L&#39;analyse histologique a montr&eacute; que les &icirc;lots transplant&eacute;s au restent hautement insuline positif, conserv&eacute; les cellules alpha et ne forment pas de d&eacute;p&ocirc;ts amylo&iuml;des. Cette &eacute;tude d&eacute;montre que marginal &icirc;lot masse porcine autogreffes ont une fonction &agrave; long terme stable, m&ecirc;me en pr&eacute;sence d&#39;une demande m&eacute;tabolique accrue. Ces r&eacute;sultats sont discordants avec les pr&eacute;c&eacute;dentes &eacute;tudes sur les animaux grands et sugg&egrave;rent que les &icirc;lots porcins peuvent &ecirc;tre r&eacute;sistants &agrave; la d&eacute;faillance m&eacute;tabolique.

&Icirc;lot de masse marginal porcine autogreffes r&eacute;sistent d&eacute;faillance m&eacute;tabolique au fil du temps et sont am&eacute;lior&eacute;s par un traitement pr&eacute;coce avec le liraglutide.

Sebbene l&#39;indipendenza di insulina &egrave; mantenuto nella maggior parte dei destinatari isolotto a 1 anno dopo trapianto, esteso follow-up ha rivelato che molti pazienti alla fine richiede terapia insulinica. Studi precedenti hanno mostrato che autoinnesti isolotto sono inclini a insufficienza cronica di grandi animali e gli esseri umani, suggerendo che gli eventi nonimmunological contribuiscano all&#39;isolotto dell&#39;innesto decadimento funzionale. Intervento precoce con terapie che promuovono la stabilit&agrave; dell&#39;innesto dovrebbe fornire un vantaggio misurabile nel tempo. In questo studio, l&#39;efficacia della long-acting glucagon-like peptide-1 analogico liraglutide &egrave; stato esplorato in un modello di trapianto autoinnesto suina isolotto massa marginale. Incubazione con liraglutide migliorata sopravvivenza isolotto suina e funzione dopo coltura prolungata. Pi&ugrave; veicolo-trattati (83%) e animali (80%) trattati con liraglutide &egrave; diventato insulino indipendente dopo autotransplantation isolotto. Anche se liraglutide terapia non migliora tassi di insulina indipendenza o livelli di glucosio nel sangue dopo il trapianto, un significativo incremento nella secrezione di insulina e risposta insulinica fase acuta &egrave; stato osservato negli animali trattati. Sorprendentemente, nessuna prova per deterioramento della funzione di innesto &egrave; stata osservata in uno qualsiasi degli animali trapiantati sopra pi&ugrave; di 18 mesi di follow-up nonostante l&#39;aumento di peso significativi; in effetti, una migliorata risposta al glucosio sviluppato nel tempo anche in animali di controllo. L&#39;analisi istologica ha mostrato che isolotti intraportally trapiantati &egrave; rimasto altamente insulina positivo, mantenne le cellule alfa e non ha fatto formare depositi di amiloide. Questo studio dimostra che marginale massa suina isolotto autoinnesti hanno funzione stabile a lungo termine, anche in presenza di una crescente domanda metabolica. Questi risultati sono discrepanti con precedenti studi su animali grandi e suggeriscono che porcino isolotti possono essere resistenti ad insufficienza metabolica.

Porcino isolotto massa marginale autoinnesti resistono insufficienza metabolica nel tempo e sono esaltate dall&#39;inizio del trattamento con liraglutide.

AEB-071 (AEB) is a specific inhibitor of protein kinase C, which prevents T-lymphocyte activation. The present study investigated the effect of AEB on rat islet allotransplantation alone or in combination with CTLA4-Ig, mycophenolate mofetil, or cyclosporine A (CsA).

Protein kinase C inhibitor, AEB-071, acts complementarily with cyclosporine to prevent islet rejection in rats.

AEB-071 (AEB) est un inhibiteur sp&eacute;cifique de la prot&eacute;ine kinase C, ce qui emp&ecirc;che l&#39;activation des lymphocytes T. La pr&eacute;sente &eacute;tude &eacute;tudi&eacute; l&#39;effet de l&#39;AEB sur allotransplantation &icirc;lot rat seul ou en combinaison avec CTLA4-Ig, mycoph&eacute;nolate mof&eacute;til ou cyclosporine A (CsA).

Inhibiteur de prot&eacute;ine kinase C, AEB-071, agit en compl&eacute;mentarit&eacute; avec la cyclosporine pour pr&eacute;venir le rejet des &icirc;lots pancr&eacute;atiques chez le rat.

AEB-071 (AEB) &egrave; un inibitore specifico della chinasi di proteina C, che impedisce l&#39;attivazione dei linfociti T. Il presente studio ha studiato l&#39;effetto di AEB su allotransplantation isolotto ratto da solo o in combinazione con CTLA4-Ig, micofenolato mofetile o ciclosporina A (CsA).

Inibitore di proteina chinasi C, AEB-071, agisce in modo complementare con ciclosporina per prevenire il rigetto di isolotto in ratti.

The culture of human islets is associated with approximately 10-20% islet loss, occasionally preventing transplantation. Preconditioning of the islets to improve postculture yields would be of immediate benefit, with the potential to increase both the number of transplanted patients and their metabolic reserve. In this study, the effect of liraglutide, a long-acting human glucagon-like peptide 1 analogue, on cultured human islets was examined. Culture with liraglutide (1 micromol/l) was associated with a preservation of islet mass (significantly more islets at 24 and 48 h, compared to control; P < or = 0.05 at 24 and 48 h) and with the presence of larger islets (P < or = 0.05 at 48 h). These observations were supported by reduced apoptosis rates after 24 h of treatment. We also demonstrated that human islet engraftment is improved in C57Bl/6-RAG(-/-) mice treated with liraglutide 200 microg/kg sc twice daily (P < or = 0.05), suggesting that liraglutide should be continued after transplantation. Overall, these data demonstrate the beneficial effect of liraglutide on cultured human islets, preserving islet mass. They support the design of clinical studies looking at the effect of liraglutide in clinical islet transplantation.

Liraglutide, a long-acting human glucagon-like peptide 1 analogue, improves human islet survival in culture.

La culture des &icirc;lots humains est associ&eacute;e &agrave; environ 10-20 % &icirc;lot perte, emp&ecirc;chant parfois transplantation. Pr&eacute;conditionnement des &icirc;lots d&#39;am&eacute;liorer les rendements seraient d&#39;avantage imm&eacute;diat, avec la possibilit&eacute; d&#39;augmenter le nombre de patients transplant&eacute;s et de leur r&eacute;serve m&eacute;tabolique. Dans cette &eacute;tude, l&#39;effet de liraglutide, un analogue de la longue dur&eacute;e d&#39;action humaine le glucagon-like peptide 1, sur des &icirc;lots humaines cultiv&eacute;es a &eacute;t&eacute; examin&eacute;. La culture avec le liraglutide (1 micromol/l) a &eacute;t&eacute; associ&eacute;e &agrave; une conservation des &icirc;lots pancr&eacute;atiques massive (significativement plus d&#39;&icirc;lots &agrave; 24 et 48 h, compar&eacute; au contr&ocirc;le ; P &lt; ou = 0,05 &agrave; 24 et 48 heures) et avec la pr&eacute;sence des plus grands &icirc;lots (P &lt; ou = 0,05 &agrave; 48 h). Ces observations ont &eacute;t&eacute; appuy&eacute;es par taux d&#39;apoptose r&eacute;duite apr&egrave;s 24 h de traitement. Nous avons aussi d&eacute;montr&eacute; cette greffe d&#39;&icirc;lots pancr&eacute;atiques humains est am&eacute;lior&eacute;e chez les souris C57Bl/6-RAG(-/-) trait&eacute;s par liraglutide 200 microg/kg sc deux fois par jour (P &lt; ou = 0,05), ce qui sugg&egrave;re que liraglutide se poursuive apr&egrave;s la transplantation. Dans l&#39;ensemble, ces r&eacute;sultats d&eacute;montrent l&#39;effet b&eacute;n&eacute;fique de liraglutide sur des &icirc;lots humains cultiv&eacute;s, pr&eacute;servant l&#39;&icirc;lot massive. Ils soutiennent la conception d&#39;&eacute;tudes cliniques, l&#39;effet de liraglutide dans la transplantation d&#39;&icirc;lots clinique.

Liraglutide, un analogue de la longue dur&eacute;e d&#39;action humaine le glucagon-like peptide 1, am&eacute;liore la survie des &icirc;lots pancr&eacute;atiques humains en culture.

La cultura umana isolotti &egrave; associata con perdita isolotto di circa 10-20%, occasionalmente evitando il trapianto. Precondizionamento delle isolette per migliorare i rendimenti postculture sarebbe di beneficio immediato, con il potenziale per aumentare il numero di pazienti trapiantati e la loro riserva metabolica. In questo studio, l&#39;effetto di liraglutide, un analogo a lunga durata d&#39;azione umana peptide glucagone-simile 1, su isolotti umane colte &egrave; stato esaminato. Cultura con liraglutide (1 micromol/l) &egrave; stata associata con una conservazione dell&#39;isolotto di massa (significativamente pi&ugrave; isolotti a 24 e 48 h, rispetto al controllo; P &lt; o = 0.05 a 24 e 48 h) e con la presenza di isolotti pi&ugrave; grandi (P &lt; o = 0.05 a 48 h). Queste osservazioni sono state sostenute da tariffe ridotte apoptosi dopo 24 h di trattamento. Abbiamo anche dimostrato che attecchimento isolotto umana &egrave; migliorata in C57Bl/6-RAG(-/-) topi trattati con liraglutide 200 microg/kg sc due volte al giorno (P &lt; o = 0.05), suggerendo che liraglutide dovrebbe essere continuata dopo il trapianto. Nel complesso, questi dati dimostrano l&#39;effetto benefico di liraglutide su isolotti umane colte, preservando l&#39;isolotto massa. Essi supportano la progettazione degli studi clinici, guardando l&#39;effetto del liraglutide nel trapianto clinico isolotto.

Liraglutide, un analogo a lunga durata d&#39;azione umana peptide glucagone-simile 1, migliora la sopravvivenza umana isoletta nella cultura.

Epithelioid hemangioendothelioma (EHE) is a low-grade, malignant vascular tumor that most commonly presents within the liver. Patients with hepatic EHE are often candidates for liver transplantation as the disease is usually multifocal at diagnosis. Although these patients achieve excellent early outcomes post-transplant, there are very few data regarding tumor markers that can further direct chemotherapy in hepatic EHE to prevent recurrent disease. The purpose of this study was to analyze the expression of the angiogenic factor vascular endothelial growth factor (VEGF) and its receptors in hepatic EHE. Six patients with hepatic EHE were assessed for liver transplantation at our center. Pathology specimens of primary and recurrent EHE were analyzed by hematoxylin and eosin staining and by immunofluorescence for VEGF, fetal liver kinase 1 (Flk-1), and fms-related tyrosine kinase 1 (Flt-1) expression. Five patients underwent liver transplantation, and 1 patient underwent liver resection. Biopsy-proven recurrent EHE occurred in 3 patients. VEGF expression was present in 100% of the EHE specimens examined, whereas Flt-1 expression was present in only 1 sample, and Flk-1 was not observed in any of the specimens. In 1 patient with recurrent hepatic EHE post-liver transplantation, a progressive increase in the VEGF fluorescence intensity and distribution was observed. In conclusion, in this series, VEGF expression was observed in all hepatic EHE specimens analyzed. These data suggest that anti-VEGF chemotherapeutic agents will be of use in patients with hepatic EHE, particularly as a means of reducing the tumor volume prior to resection, as a means of treating unresectable or metastatic disease, or as an adjuvant therapy in the setting of liver transplantation.

Vascular endothelial growth factor expression in hepatic epithelioid hemangioendothelioma: Implications for treatment and surgical management.

Hemangioendothelioma &eacute;pith&eacute;lio&iuml;de (EHE) est une tumeur vasculaire de bas grade, maligne que la majeure partie est g&eacute;n&eacute;ralement pr&eacute;sente dans le foie. Atteintes h&eacute;patique EHE sont souvent candidats &agrave; une transplantation h&eacute;patique, car cette maladie est g&eacute;n&eacute;ralement multifocale au moment du diagnostic. Bien que ces patients atteindre d&eacute;but excellent r&eacute;sultats suivant la greffe, il y a tr&egrave;s peu de donn&eacute;es concernant les marqueurs tumoraux qui peuvent diriger plus de chimioth&eacute;rapie dans EHE h&eacute;patique &agrave; pr&eacute;venir les maladies r&eacute;currentes. Le but de cette &eacute;tude &eacute;tait d&#39;analyser l&#39;expression de l&#39;angiog&eacute;nique facteur vascular endothelial growth factor (VEGF) et de ses r&eacute;cepteurs dans EHE h&eacute;patique. Six patients avec EHE h&eacute;patique ont &eacute;t&eacute; &eacute;valu&eacute;s pour une transplantation du foie &agrave; notre centre. Des sp&eacute;cimens de pathologie de EHE primaire et r&eacute;currente ont &eacute;t&eacute; analys&eacute;s par l&#39;h&eacute;matoxyline et &eacute;osine coloration et par immunofluorescence pour VEGF, foetale du foie 1 (Flk-1) et ax&eacute;s sur le fms tyrosine kinase 1 (Flt-1) expression. Cinq patients ont subi une greffe du foie, et 1 patient a subi une r&eacute;section h&eacute;patique. Biopsie a fait ses preuves r&eacute;currente EHE s&#39;est produite chez 3 patients. Expression du VEGF &eacute;tait pr&eacute;sente dans 100 % des sp&eacute;cimens EHE examin&eacute;s, alors que l&#39;expression Flt-1 &eacute;tait pr&eacute;sente dans 1 seul &eacute;chantillon et Flk-1 n&#39;a pas &eacute;t&eacute; observ&eacute;e dans l&#39;un des sp&eacute;cimens. Chez 1 patient avec r&eacute;currente transplantation h&eacute;patique de EHE post-h&eacute;patique, on a observ&eacute; une augmentation progressive de l&#39;intensit&eacute; de fluorescence de VEGF et de la distribution. En conclusion, dans cette s&eacute;rie, expression du VEGF a &eacute;t&eacute; observ&eacute;e chez tous les sp&eacute;cimens EHE h&eacute;patiques analys&eacute;s. Ces donn&eacute;es sugg&egrave;rent que les agents chimioth&eacute;rapeutiques anti-VEGF sera utile chez les patients avec EHE h&eacute;patique, surtout comme un moyen de r&eacute;duire le volume de la tumeur avant la r&eacute;section, comme un moyen de soigner des maladies non r&eacute;s&eacute;cable ou m&eacute;tastatique, ou comme traitement adjuvant dans le cadre d&#39;une transplantation h&eacute;patique.

Facteur de croissance endoth&eacute;lial vasculaire expression h&eacute;patique hemangioendothelioma &eacute;pith&eacute;lio&iuml;de : Implications pour le traitement et la prise en charge chirurgicale.

Epitelioidi kaposiforme (EHE) &egrave; un tumore vascolare maligno, bassa qualit&agrave; che pi&ugrave; comunemente presenta all&#39;interno del fegato. I pazienti con EHE epatica sono spesso candidati per il trapianto di fegato come la malattia &egrave; di solito multifocale al momento della diagnosi. Sebbene questi pazienti raggiungere i primi risultati eccellenti post-transplant, ci sono pochissimi dati per quanto riguarda i marcatori tumorali che possono ulteriormente diretto chemioterapia in EHE epatica a prevenire le malattie ricorrenti. Lo scopo di questo studio era di analizzare l&#39;espressione dell&#39;angiogenico fattore vascular endothelial growth factor (VEGF) e suoi recettori in EHE epatica. Sei pazienti con EHE epatica sono stati valutati per il trapianto di fegato presso il nostro centro. Esemplari di patologia di EHE primarie e ricorrenti sono stati analizzati da ematossilina ed eosina di colorazione e di immunofluorescenza per VEGF chinasi 1 (Flk-1) di fegato fetale e relativi fms tirosina chinasi 1 (Flt-1) espressione. Cinque pazienti sono stati sottoposti a trapianto di fegato, e 1 paziente ha subito la resezione epatica. Biopsia-provata ricorrenti EHE si &egrave; verificato in 3 pazienti. Espressione di VEGF &egrave; stata presente nel 100% dei campioni di EHE esaminati, considerando che l&#39;espressione Flt-1 era presente in 1 solo campione, e Flk-1 non &egrave; stata osservata in nessuno dei campioni. In 1 paziente con ricorrente trapianto EHE post-liver epatico, &egrave; stato osservato un aumento progressivo dell&#39;intensit&agrave; di fluorescenza di VEGF e distribuzione. In conclusione, in questa serie, espressione di VEGF &egrave; stata osservata in tutti i campioni EHE epatici analizzati. Questi dati suggeriscono che gli agenti chemioterapici anti-VEGF sar&agrave; di uso in pazienti con EHE epatica, specialmente come mezzo per ridurre il volume del tumore prima della resezione, come mezzo di trattamento della malattia metastatica o unresectable, o come terapia adiuvante nella cornice del trapianto di fegato.

Espressione di vascular endothelial growth factor in kaposiforme epitelioide epatico: implicazioni per il trattamento e la gestione chirurgica.

Islet transplantation has become a viable option for selected type 1 diabetic patients; however, a significant portion need to return to exogenous insulin. The predominant factors include impaired islet engraftment and early islet loss. Caspase inhibition is a potent way to improve islet engraftment, but all tested compounds so far have not been clinically relevant. IDN-6556 (PF3491390) has already been used clinically and can be delivered orally with high portal vein concentrations.

The caspase inhibitor IDN-6556 (PF3491390) improves marginal mass engraftment after islet transplantation in mice.

Transplantation d&#39;&icirc;lots pancr&eacute;atiques est devenu une option viable pour les patients diab&eacute;tiques de type s&eacute;lectionn&eacute; 1 ; Toutefois, une partie importante vous devrez remettre &agrave; l&#39;insuline exog&egrave;ne. Les facteurs pr&eacute;dominants comprennent la greffe d&#39;&icirc;lots avec facult&eacute;s affaiblies et de la perte pr&eacute;coce d&#39;&icirc;lot. Inhibition de la caspase est un moyen puissant pour am&eacute;liorer la greffe d&#39;&icirc;lots pancr&eacute;atiques, mais tous les compos&eacute;s test&eacute;s jusqu&#39;&agrave; pr&eacute;sent n&#39;ont pas &eacute;t&eacute; cliniquement pertinentes. IDN-6556 (PF3491390) a d&eacute;j&agrave; &eacute;t&eacute; utilis&eacute; en clinique et peut &ecirc;tre livr&eacute;s par voie orale avec des concentrations de la veine porte haute.

L&#39;inhibiteur de la caspase IDN-6556 (PF3491390) am&eacute;liore marginal greffe massive apr&egrave;s transplantation d&#39;&icirc;lots pancr&eacute;atiques chez la souris.

Trapianto isolotto &egrave; diventata una valida opzione per i pazienti diabetici di tipo selezionato 1; Tuttavia, una parte significativa devono restituire all&#39;insulina esogena. I fattori predominanti includono alterata isolotto attecchimento e precoce perdita di isoletta. Inibizione di caspase &egrave; un modo potente per migliorare l&#39;attecchimento isolotto, ma tutti i composti testati finora non sono stati clinicamente rilevanti. IDN-6556 (PF3491390) &egrave; gi&agrave; stato utilizzato clinicamente e possono essere consegnati per via orale con vena portale ad alta concentrazione.

L&#39;inibitore di caspasi IDN-6556 (PF3491390) migliora marginale massa attecchimento dopo trapianto isolotto nei topi.

Islet transplantation has become a very promising treatment for type 1 diabetes. To facilitate further clinical improvements in this exciting field, rodent islets are used to evaluate new strategies and modifications. One method to purify islets is on a density gradient, although the optimal gradient component can be debated. N=6 separate mouse islet isolations were used and the resulting islets were separated and purified on either a Ficoll, Histopaque, Dextran or Iodixanol gradient. Islets were assessed for recovery, viability, purity and in vitro functionality. Aliquots were transplanted into diabetic mice to assess in vivo functionality and survival. There was no difference in the number of islets recovered across groups nor in the size of recovered islets. Use of a Ficoll or Histopaque gradient led to the most pure and viable islets in comparison to Dextran and Iodixanol. Functionally, islets isolated on a Ficoll gradient had the highest glucose-stimulated insulin release in vitro while performing equally to Histopaque and Dextran gradients in vivo. Using a Ficoll gradient, however, comes at a higher monetary cost. We recommend using a Histopaque gradient, which led to the isolation of viable and functional islets with a reduced cost as compared to a Ficoll gradient.

Histopaque provides optimal mouse islet purification kinetics: comparison study with Ficoll, iodixanol and dextran.

AEB071 (AEB, sotrastaurin), a specific inhibitor of protein kinase C, reduces T-lymphocyte activation and cytokine release. AEB delays islet allograft rejection in rats and prevents rejection when combined with cyclosporine. Since many immunosuppressive agents have toxic effects on the function of transplanted islets, we investigated whether this was also the case with AEB. Human islets were transplanted into Rag-knockout mice randomly assigned to vehicle control, AEB or sirolimus treatment groups. Non-fasting blood glucose levels, body weight and glucose tolerance was measured in recipients. In a separate experiment, human islets were cultured in the presence of AEB and assayed for glucose dependent insulin secretion and level of Î²-cell apoptosis. Eighty-six percent of the AEB-treated recipients achieved normoglycemia following transplant (compared with none in sirolimus-treated group, p < 0.05). AEB-treated recipients exhibited similar glucose homeostasis as vehicle-treated controls, which was better than in sirolimus-treated recipients. Human islets cultured with AEB showed similar rates of Î²-cell apoptosis (p = 0.98 by one-way ANOVA) and glucose stimulated insulin secretion (p = 0.15) as those cultured with vehicle. These results suggest that AEB is not associated with toxic effects on islet engraftment or function. AEB appears to be an appropriate immunosuppressive candidate for clinical trials in islet transplantation.

AEB071 (sotrastaurin) does not exhibit toxic effects on human islets in vitro, nor after transplantation into immunodeficient mice.

AEB071 (AEB, sotrastaurine), un inhibiteur sp&eacute;cifique de la prot&eacute;ine kinase C, r&eacute;duit l&#39;activation des lymphocytes T et des cytokines. AEB retarde le rejet d&#39;allogreffes &icirc;lot chez le rat et emp&ecirc;che le rejet lorsqu&#39;il est combin&eacute; avec la cyclosporine. &Eacute;tant donn&eacute; que beaucoup d&#39;agents immunosuppresseurs ont des effets toxiques sur la fonction des &icirc;lots transplant&eacute;s, nous avons &eacute;tudi&eacute; si c&#39;&eacute;tait aussi le cas avec AEB. &Icirc;lots humains ont &eacute;t&eacute; transplant&eacute;es dans des souris Rag-al&eacute;atoirement dans v&eacute;hicule contr&ocirc;le, AEB ou sirolimus groupes de traitement. Taux de glucose sanguin non-je&ucirc;ne, tol&eacute;rance de glucose et de poids corps a &eacute;t&eacute; mesur&eacute;e chez des receveurs. Dans une exp&eacute;rience distincte, &icirc;lots humains ont &eacute;t&eacute; cultiv&eacute;es en pr&eacute;sence de l&#39;AEB et test&eacute;s pour la s&eacute;cr&eacute;tion d&#39;insuline d&eacute;pendant de glucose et de niveau de l&#39;apoptose des cellules &beta;. Quatre-vingt-six pour cent des destinataires impr&eacute;gn&eacute;es d&#39;AEB atteint normoglyc&eacute;mie apr&egrave;s transplantation (compar&eacute;e &agrave; z&eacute;ro dans le groupe trait&eacute; sirolimus, p &lt; 0,05). Impr&eacute;gn&eacute;es d&#39;AEB destinataires expos&eacute; semblable hom&eacute;ostasie du glucose comme t&eacute;moins trait&eacute;s v&eacute;hicule, qui &eacute;tait mieux que chez les receveurs impr&eacute;gn&eacute;es de sirolimus. &Icirc;lots humains cultiv&eacute;s avec AEB a montr&eacute; des taux similaires de l&#39;apoptose des cellules &beta; (p = 0,98 par ANOVA &agrave;) et glucose stimule la s&eacute;cr&eacute;tion d&#39;insuline (p = 0, 15) que celles cultiv&eacute;es avec v&eacute;hicule. Ces r&eacute;sultats sugg&egrave;rent que l&#39;AEB n&#39;est pas associ&eacute;e &agrave; des effets toxiques sur la greffe d&#39;&icirc;lots pancr&eacute;atiques ou de la fonction. AEB semble &ecirc;tre un bon candidat immunosuppresseur pour des essais cliniques dans la transplantation d&#39;&icirc;lots.

AEB071 (sotrastaurine) ne pr&eacute;sente pas d&#39;effets toxiques sur les &icirc;lots humains in vitro, ni apr&egrave;s transplantation chez des souris immunod&eacute;ficientes.

AEB071 (AEB, sotrastaurin), un inibitore specifico della chinasi di proteina C, riduce l&#39;attivazione dei linfociti T e rilascio di citochine. AEB ritardi rifiuto allotrapianto isolotto nei ratti e impedisce il rigetto quando combinato con ciclosporina. Dal momento che molti agenti immunosoppressivi hanno effetti tossici sulla funzione del trapiantati isolotti, abbiamo studiato se questo era inoltre il caso con AEB. Isolotti umane sono stati trapiantati in topi Rag-knockout casualmente assegnati a gruppi di trattamento di controllo, AEB o sirolimus veicolo. Livelli di glucosio nel sangue non digiuno, corpo peso e glicemia la tolleranza &egrave; stata misurata in destinatari. In un esperimento separato, isolotti umane sono state coltivate in presenza di AEB e dosati per la secrezione di insulina dipendente da glucosio e il livello di apoptosi delle cellule &beta;. Ottantasei per cento dei destinatari AEB-trattati raggiunto normoglycemia dopo trapianto (confrontato con nessuno nel gruppo trattato sirolimus, p &lt; 0,05). Destinatari AEB-trattato esposto simili omeostasi del glucosio come controlli trattati con veicolo, che era meglio che nei trattati di sirolimus destinatari. Isolotti umane coltivate con AEB ha mostrato i tassi simili di apoptosi delle cellule &beta; (p = 0,98 da One-way ANOVA) e glucosio stimolata la secrezione di insulina (p = 0,15) come quelli coltivati con il veicolo. Questi risultati suggeriscono che la AEB non &egrave; associato a effetti tossici sulla funzione o attecchimento isolotto. AEB sembra essere un potenziale candidato immunosoppressore per studi clinici di trapianto isolotto.

AEB071 (sotrastaurin) non mostrano effetti tossici su isolotti umane in vitro, n&eacute; dopo il trapianto in topi immunodeficienti.

Proth&#xE9;tiques est fr&#xE9;quemment utilis&#xE9; dans la reconstruction mur hernie abdominale, mais est sujette &#xE0; la formation d&#x26;#39;adh&#xE9;rences postop&#xE9;ratoires. Les complications r&#xE9;sultant de adh&#xE9;rences intra-abdominales repr&#xE9;sentent un fardeau consid&#xE9;rable clinique et la rentabilit&#xE9;. Nous, ici, d&#x26;#39;&#xE9;tudier les propri&#xE9;t&#xE9;s anti-prolif&#xE9;ratives et antiadhesiogenic de sirolimus et hydrogel impr&#xE9;gn&#xE9;, &#xE0; &#xE9;lution m&#xE9;dicamenteuse mailles &#xE0; diminuer ces complications dans un mod&#xE8;le murin de la r&#xE9;paration du mur hernie abdominale.

Le sirolimus &#xE0; &#xE9;lution m&#xE9;dicamenteuse, un hydrogel impr&#xE9;gn&#xE9; maille de polypropyl&#xE8;ne R&#xE9;duit la formation d&#x26;#39;adh&#xE9;rences intra-abdominales dans un mod&#xE8;le murin

Prothetische Masche wird verwendet h&auml;ufig Bauchdecke Hernie Wiederaufbau aber anf&auml;llig f&uuml;r postoperative Adh&auml;sion Bildung. Komplikationen infolge intraabdominellen Adh&auml;sionen stellen eine erhebliche klinische und Kostenbelastung. Hier untersuchen wir, die Antiproliferative und Antiadhesiogenic Eigenschaften von Sirolimus und Hydrogel-impr&auml;gniert, Drug-eluting Masche um solche Komplikationen in einem Mausmodell der Bauchdecke Hernie Reparatur zu verringern.

Sirolimus Drug-eluting, Hydrogel-impr&auml;gniert-Polypropylen-Netz reduziert intraabdominellen Adh&auml;sion-Formation in einem Mausmodell.

Maglie protesiche sono usata frequentemente nella ricostruzione ernia della parete addominale ma sono incline alla formazione di aderenze postoperatorie. Complicazioni derivanti da aderenze intra-addominale rappresentano un considerevole cliniche e costi oneri. Nel presente documento, indaghiamo le propriet&agrave; antiproliferativa e antiadhesiogenic del sirolimus e maglia impregnata di idrogel, medicati per diminuire tali complicazioni in un modello murino di riparazione di ernia di parete addominale.

Rete in polipropilene a sirolimus medicati, impregnata di idrogel riduce la formazione di aderenze intra-addominale in un modello murino.

Prosthetic mesh is used frequently in abdominal wall hernia reconstruction but is prone to postoperative adhesion formation. Complications resulting from intra-abdominal adhesions represent a considerable clinical and cost burden. We, herein, investigate the antiproliferative and antiadhesiogenic properties of sirolimus and hydrogel-impregnated, drug-eluting mesh to decrease such complications in a mouse model of abdominal wall hernia repair.

Sirolimus drug-eluting, hydrogel-impregnated polypropylene mesh reduces intra-abdominal adhesion formation in a mouse model.

&#x5047;&#x80A2;&#x7F51;&#x5E38;&#x7528;&#x4E8E;&#x8179;&#x58C1;&#x759D;&#x91CD;&#x5EFA;&#xFF0C;&#x4F46;&#x5BB9;&#x6613;&#x51FA;&#x73B0;&#x672F;&#x540E;&#x7C98;&#x8FDE;&#x5F62;&#x6210;&#x3002;&#x56E0;&#x8179;&#x5185;&#x7C98;&#x8FDE;&#x5F15;&#x8D77;&#x5E76;&#x53D1;&#x75C7;&#x8868;&#x793A;&#x5927;&#x91CF;&#x4E34;&#x5E8A;&#x548C;&#x6210;&#x672C;&#x8D1F;&#x62C5;&#x3002;&#x6211;&#x4EEC;&#xFF0C;&#x672C;&#x6587;&#x6240;&#x8FF0;&#xFF0C;&#x8C03;&#x67E5;&#x7684;&#x6297;&#x589E;&#x6B96;&#x548C; antiadhesiogenic &#x5C5E;&#x6027;&#x7684;&#x897F;&#x7F57;&#x83AB;&#x53F8;&#x548C;&#x6C34;&#x51DD;&#x80F6;&#x6D78;&#x6E0D;&#x3001; &#x836F;&#x7269;&#x6D17;&#x8131;&#x7684;&#x7F51;&#x683C;&#xFF0C;&#x4EE5;&#x51CF;&#x5C11;&#x8FD9;&#x79CD;&#x5C0F;&#x9F20;&#x6A21;&#x578B;&#x7684;&#x8179;&#x58C1;&#x759D;&#x4FEE;&#x8865;&#x672F;&#x7684;&#x5E76;&#x53D1;&#x75C7;&#x3002;

&#x897F;&#x7F57;&#x83AB;&#x53F8;&#x836F;&#x7269;&#x6D17;&#x8131;&#x3001; &#x6C34;&#x51DD;&#x80F6;&#x6D78;&#x6E0D;&#x7684;&#x805A;&#x4E19;&#x70EF;&#x7F51;&#x51CF;&#x5C11;&#x4E86;&#x6A21;&#x578B;&#x5C0F;&#x9F20;&#x7684;&#x8179;&#x8154;&#x7C98;&#x8FDE;&#x5F62;&#x6210;&#x3002;

&#x88DC;&#x7DB4;&#x30E1;&#x30C3;&#x30B7;&#x30E5;&#x3092;&#x8179;&#x58C1;&#x30D8;&#x30EB;&#x30CB;&#x30A2;&#x306E;&#x518D;&#x69CB;&#x7BC9;&#x3067;&#x983B;&#x7E41;&#x306B;&#x4F7F;&#x7528;&#x3055;&#x308C;&#x307E;&#x3059;&#x304C;&#x3001;&#x8853;&#x5F8C;&#x306E;&#x7652;&#x7740;&#x5F62;&#x6210;&#x3057;&#x3084;&#x3059;&#x3044;&#x3067;&#x3059;&#x3002;&#x8179;&#x8154;&#x5185;&#x7652;&#x7740;&#x306B;&#x8D77;&#x56E0;&#x3059;&#x308B;&#x5408;&#x4F75;&#x75C7;&#x306F;&#x3001;&#x304B;&#x306A;&#x308A;&#x306E;&#x81E8;&#x5E8A;&#x7684;&#x304A;&#x3088;&#x3073;&#x30B3;&#x30B9;&#x30C8;&#x8CA0;&#x62C5;&#x3092;&#x8868;&#x3057;&#x3066;&#x3044;&#x307E;&#x3059;&#x3002;&#x6211;&#x3005;&#x306F;&#x3001;&#x3053;&#x3053;&#x3067;&#x306F;&#x3001;&#x8179;&#x58C1;&#x30D8;&#x30EB;&#x30CB;&#x30A2;&#x4FEE;&#x5FA9;&#x306E;&#x30DE;&#x30A6;&#x30B9;&#x30E2;&#x30C7;&#x30EB;&#x3067;&#x3053;&#x306E;&#x3088;&#x3046;&#x306A;&#x5408;&#x4F75;&#x75C7;&#x3092;&#x6E1B;&#x5C11;&#x3055;&#x305B;&#x308B;&#x30B7;&#x30ED;&#x30EA;&#x30E0;&#x30B9;&#x3068;&#x30CF;&#x30A4;&#x30C9;&#x30ED;&#x30B2;&#x30EB;&#x3092;&#x542B;&#x6D78;&#x3055;&#x305B;&#x3001;&#x85AC;&#x5264;&#x6EB6;&#x51FA;&#x578B;&#x30E1;&#x30C3;&#x30B7;&#x30E5;&#x306E;&#x5897;&#x6B96;&#x3068;antiadhesiogenic&#x7279;&#x6027;&#x3092;&#x8ABF;&#x3079;&#x308B;&#x3002;

&#x30B7;&#x30ED;&#x30EA;&#x30E0;&#x30B9;&#x85AC;&#x5264;&#x6EB6;&#x51FA;&#x578B;&#x3001;&#x30CF;&#x30A4;&#x30C9;&#x30ED;&#x30B2;&#x30EB;&#x3092;&#x542B;&#x6D78;&#x3055;&#x305B;&#x305F;&#x30DD;&#x30EA;&#x30D7;&#x30ED;&#x30D4;&#x30EC;&#x30F3;&#x30E1;&#x30C3;&#x30B7;&#x30E5;&#x306F;&#x3001;&#x30DE;&#x30A6;&#x30B9;&#x30E2;&#x30C7;&#x30EB;&#x306B;&#x304A;&#x3051;&#x308B;&#x8179;&#x8154;&#x5185;&#x7652;&#x7740;&#x5F62;&#x6210;&#x3092;&#x4F4E;&#x6E1B;

&#xBCF4; &#xCCA0; &#xB9DD; &#xBCF5; &#xBCBD; &#xD0C8; &#xC7A5; &#xC7AC;&#xAC74;&#xC5D0; &#xC790;&#xC8FC; &#xC0AC;&#xC6A9; &#xB418;&#xC9C0;&#xB9CC; &#xC218;&#xC220; &#xD6C4; &#xC811;&#xCC29; &#xB825; &#xD615;&#xC131; &#xD558;&#xB294; &#xACBD;&#xD5A5;&#xC774; &#xC788;&#xB2E4;. &#xB0B4;&#xBD80;&#xC758; &#xC720;&#xCC29;&#xC5D0;&#xC11C; &#xBC1C;&#xC0DD; &#xD558;&#xB294; &#xD569;&#xBCD1;&#xC99D; &#xC0C1;&#xB2F9;&#xD55C; &#xC784;&#xC0C1; &#xBC0F; &#xBE44;&#xC6A9; &#xBD80;&#xB2F4;&#xC744; &#xB098;&#xD0C0;&#xB0C5;&#xB2C8;&#xB2E4;. &#xC6B0;&#xB9AC;&#xB294; &#xC5EC;&#xAE30;, sirolimus &#xBC0F; &#xBCF5; &#xBCBD; &#xD0C8; &#xC7A5; &#xC218;&#xB9AC;&#xC758; &#xB9C8;&#xC6B0;&#xC2A4; &#xBAA8;&#xB378;&#xC5D0; &#xC774;&#xB7EC;&#xD55C; &#xD569;&#xBCD1;&#xC99D;&#xC744; &#xAC10;&#xC18C; hydrogel &#xC218;&#xD0DC;, &#xC57D; eluting &#xBA54;&#xC26C; antiproliferative &#xBC0F; antiadhesiogenic &#xC18D;&#xC131;&#xC744; &#xC870;&#xC0AC; &#xD569;&#xB2C8;&#xB2E4;.

Sirolimus &#xC57D; eluting hydrogel &#xC218;&#xD0DC;, &#xD3F4; &#xB9AC; &#xD504;&#xB85C;&#xD544; &#xB80C; &#xBA54;&#xC26C; &#xB9C8;&#xC6B0;&#xC2A4; &#xBAA8;&#xB378;&#xC5D0;&#xC11C; &#xB0B4;&#xBD80;&#xC758; &#xC811;&#xCC29; &#xB825;&#xC744; &#xD615;&#xC131;&#xC744; &#xAC10;&#xC18C; &#xC2DC;&#xD0A8;&#xB2E4;.

Malla prot&#xE9;sica se utiliza con frecuencia en la reconstrucci&#xF3;n de hernia de la pared abdominal, pero es propenso a la formaci&#xF3;n de adherencias postoperatorias. Las complicaciones derivadas de adherencias intraabdominales representan una considerable carga cl&#xED;nica y econ&#xF3;mica. Nosotros, aqu&#xED;, investigar las propiedades antiproliferativas y antiadhesiogenic de sirolimus y de hidrogel impregnado, recubierto de f&#xE1;rmacos de malla para reducir estas complicaciones en un modelo murino de la reparaci&#xF3;n de hernia de la pared abdominal.

Sirolimus liberador de f&#xE1;rmaco, hidrogel impregnado con malla de polipropileno reduce intra-abdominal formaci&#xF3;n de adherencias en un modelo de rat&#xF3;n

Large numbers of islets are lost in the early phase after clinical islet transplantation, through apoptosis, necrosis, or innate inflammatory injury. We previously demonstrated the efficacy of a series of caspase inhibitors in mouse models on islet engraftment through reduction in early posttransplant apoptosis. We studied IDN6556, a caspase inhibitor with a first-pass effect, in a large animal (pig) intraportal marginal mass islet autotransplant model.

ArticleTotal : 2	Year
Publication title	2022
Publication title Cited by 1	2022

Article	Year
Effect of different induction strategies on effector, regulatory and memory lymphocyte sub-populations in clinical islet transplantation. Transplant international : official journal of the European Society for Organ Transplantation\| PubMed ID: 18713144	2009
Porcine marginal mass islet autografts resist metabolic failure over time and are enhanced by early treatment with liraglutide. Endocrinology\| PubMed ID: 19131571	2009
Protein kinase C inhibitor, AEB-071, acts complementarily with cyclosporine to prevent islet rejection in rats. Transplantation\| PubMed ID: 19136892	2009
Liraglutide, a long-acting human glucagon-like peptide 1 analogue, improves human islet survival in culture. Transplant international : official journal of the European Society for Organ Transplantation\| PubMed ID: 19821955	2010
Vascular endothelial growth factor expression in hepatic epithelioid hemangioendothelioma: Implications for treatment and surgical management. Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society\| PubMed ID: 20104492	2010
The caspase inhibitor IDN-6556 (PF3491390) improves marginal mass engraftment after islet transplantation in mice. Surgery\| PubMed ID: 21596412	2011
Histopaque provides optimal mouse islet purification kinetics: comparison study with Ficoll, iodixanol and dextran. Islets\| PubMed ID: 21606673	2011
AEB071 (sotrastaurin) does not exhibit toxic effects on human islets in vitro, nor after transplantation into immunodeficient mice. Islets\| PubMed ID: 21934354	2011
Sirolimus drug-eluting, hydrogel-impregnated polypropylene mesh reduces intra-abdominal adhesion formation in a mouse model. Surgery\| PubMed ID: 21943642	2011
Caspase inhibitor IDN6556 facilitates marginal mass islet engraftment in a porcine islet autotransplant model. Transplantation\| PubMed ID: 22706322	2012

Ryan Edgar

Biography

JoVE Journal Publications

Other Publications